Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FATE Fate Therapeutics

Market Closed 05-03 16:00:00 EDT

4.06

-0.04

-0.98%

盘后4.18

+0.12+2.96%

19:52 EDT

High4.50	Low4.05	Vol2.02M
Open4.30	D1 Closing4.10	Amplitude10.98%
Mkt Cap462.10M	Tradable Cap375.56M	Total Shares113.82M
T/O8.52M	T/O Rate2.19%	Tradable Shares92.50M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics","latestPrice":4.06,"timestamp":1714766400000,"preClose":4.1,"halted":0,"volume":2024984,"hourTrading":{"tag":"盘后","latestPrice":4.18,"preClose":4.06,"latestTime":"19:52 EDT","volume":61012,"amount":248287.6672,"timestamp":1714780335560},"delay":0,"floatShares":92501638,"shares":113816708,"eps":-1.64,"marketStatus":"Market Closed","change":-0.04,"latestTime":"05-03 16:00:00 EDT","open":4.3,"high":4.5,"low":4.05,"amount":8515612.565616,"amplitude":0.109756,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.64,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1714982400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":4.1,"postHourTrading":{"tag":"盘后","latestPrice":4.18,"preClose":4.06,"latestTime":"19:52 EDT","volume":61012,"amount":248287.6672,"timestamp":1714780335560},"volumeRatio":0.5542423907121886},"requestUrl":"/m/hq/s/FATE/tweets","defaultTab":"tweets","newsList":[{"id":"2433481988","title":"Wall Street Breakfast: The Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2433481988","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2433481988?lang=en_us&edition=fundamental","pubTime":"2024-05-05 18:27","pubTimestamp":1714904867,"startTime":"0","endTime":"0","summary":"Listen on the go!","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458971009/image_458971009.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458971009/image_458971009.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4689591-wall-street-breakfast-week-ahead","is_publish_highlight":false,"gpt_icon":0},{"id":"2432146554","title":"Eyes On Apple, Uber, Disney, Rivian And Coupang","url":"https://stock-news.laohu8.com/highlight/detail?id=2432146554","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432146554?lang=en_us&edition=fundamental","pubTime":"2024-05-04 22:00","pubTimestamp":1714831200,"startTime":"0","endTime":"0","summary":"Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make h","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4688679-eyes-on-apple-uber-disney-rivian-and-coupang","is_publish_highlight":false,"gpt_icon":0},{"id":"2432913156","title":"Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2432913156","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2432913156?lang=en_us&edition=fundamental","pubTime":"2024-05-03 20:30","pubTimestamp":1714739400,"startTime":"0","endTime":"0","summary":"Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells ADR Technology Incorporated into FT522 Induces Functional Persistence and Eliminat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/03/2875365/24675/en/Fate-Therapeutics-Announces-Presentation-of-FT522-Preclinical-Data-for-Autoimmune-Diseases-in-Late-breaking-Abstract-at-ASGCT-Annual-Meeting.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431689248","title":"Fate Therapeutics: Looking For A Potential Turnaround In 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2431689248","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2431689248?lang=en_us&edition=fundamental","pubTime":"2024-04-30 00:09","pubTimestamp":1714406991,"startTime":"0","endTime":"0","summary":"Fate Therapeutics has faced setbacks, including the termination of a partnership with Janssen Pharmaceuticals, but upcoming clinical milestones could reset the bull thesis.The company's iPSCs technolo","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1966392917/image_1966392917.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1966392917/image_1966392917.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4687226-fate-therapeutics-looking-for-a-potential-turnaround-in-2024","is_publish_highlight":false,"gpt_icon":0},{"id":"2429147113","title":"Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2429147113","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2429147113?lang=en_us&edition=fundamental","pubTime":"2024-04-24 03:23","pubTimestamp":1713900206,"startTime":"0","endTime":"0","summary":"Fate Therapeutics, Inc. ( NASDAQ:FATE ) shares have retraced a considerable 28% in the last month, reversing a fair...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fate/fate-therapeutics/news/fate-therapeutics-incs-nasdaqfate-28-dip-in-price-shows-sent","is_publish_highlight":false,"gpt_icon":0},{"id":"2429145338","title":"Fate Therapeutics Currently Down 10 Consecutive Days, on Pace for Longest Losing Streak Since December 2022 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2429145338","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2429145338?lang=en_us&edition=fundamental","pubTime":"2024-04-24 02:09","pubTimestamp":1713895740,"startTime":"0","endTime":"0","summary":"Fate Therapeutics, Inc.  is currently at $4.58, down $0.21 or 4.29%. --Would be lowest close since Jan. 26, 2024, when it closed at $4.56. --Currently down 10 consecutive days; down 32.32% over this period. --Longest losing streak since Dec. 28, 2022, when it fell for 10 straight trading days. --Down 37.67% month-to-date; on pace for worst month since Aug. 2023, when it fell 39.23%. --Down 96.1% from its all-time closing high of $117.40 on Jan. 14, 2021. --Down 24.13% from 52 weeks ago , when it closed at $6.03. --Up 177.27% from its 52-week closing low of $1.65 on Oct. 27, 2023. --Traded as low as $4.49; lowest intraday level since Jan. 29, 2024, when it hit $4.43","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2428542916","title":"Fate Therapeutics files to sell 3.64M shares for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2428542916","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2428542916?lang=en_us&edition=fundamental","pubTime":"2024-04-19 04:32","pubTimestamp":1713472327,"startTime":"0","endTime":"0","summary":"Fate Therapeutics  on Thursday filed a prospectus related to a proposed resale of about 3.64M shares of its common stock by selling stockholders.This prospectus is not an offer to sell these securities.More on Fate Therapeutics  Fate Therapeutics, Inc.  Q4 2023 Earnings Call Transcript Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks Fate Therapeutics announces pricing of $100M underwritten offering and concurrent private placement Seeking Alpha’s Quant Rating on Fate Therapeutics Historical earnings data for Fate Therapeutics","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4091278-fate-therapeutics-files-to-sell-364m-shares-for-holders","is_publish_highlight":false,"gpt_icon":0},{"id":"2426232844","title":"Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Disc Medicine (IRON) and Avita Medical (RCEL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2426232844","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2426232844?lang=en_us&edition=fundamental","pubTime":"2024-04-11 18:20","pubTimestamp":1712830816,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fate Therapeutics (FATE – Research Report), Disc M...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-fate-therapeutics-fate-disc-medicine-iron-and-avita-medical-rcel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-fate-therapeutics-fate-disc-medicine-iron-and-avita-medical-rcel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2426198091","title":"Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2426198091","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2426198091?lang=en_us&edition=fundamental","pubTime":"2024-04-09 18:05","pubTimestamp":1712657154,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics is experiencing a favorable moment following FDA approval for its melanoma drug Amtagvi and a successful underwritten offering.The company has developed its own production capa","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487494602/image_1487494602.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487494602/image_1487494602.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4682837-iovance-biotherapeutics-riding-the-favorable-moment-could-bring-excellent-results","is_publish_highlight":false,"gpt_icon":0},{"id":"2424814133","title":"Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2424814133","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2424814133?lang=en_us&edition=fundamental","pubTime":"2024-04-03 12:00","pubTimestamp":1712116800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  03, 2024  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/03/2856877/24675/en/Fate-Therapeutics-to-Present-at-23rd-Annual-Needham-Virtual-Healthcare-Conference.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424907226","title":"Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2424907226","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2424907226?lang=en_us&edition=fundamental","pubTime":"2024-04-03 04:01","pubTimestamp":1712088060,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23015552","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0684},{"period":"1month","weight":-0.4208},{"period":"3month","weight":-0.3773},{"period":"6month","weight":0.6987},{"period":"1year","weight":-0.342},{"period":"ytd","weight":0.0856}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.0343},{"period":"6month","weight":0.1762},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0757}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.058546},{"month":2,"riseRate":0.636364,"avgChangeRate":0.08272},{"month":3,"riseRate":0.545455,"avgChangeRate":0.019657},{"month":4,"riseRate":0.545455,"avgChangeRate":-0.055265},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.008156},{"month":6,"riseRate":0.6,"avgChangeRate":0.022155},{"month":7,"riseRate":0.4,"avgChangeRate":-0.000476},{"month":8,"riseRate":0.4,"avgChangeRate":0.007076},{"month":9,"riseRate":0.4,"avgChangeRate":-0.015658},{"month":10,"riseRate":0.2,"avgChangeRate":-0.084781},{"month":11,"riseRate":0.545455,"avgChangeRate":0.090798},{"month":12,"riseRate":0.636364,"avgChangeRate":0.109378}],"exchange":"NASDAQ","name":"Fate Therapeutics","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fate Therapeutics,FATE,Fate Therapeutics股票,Fate Therapeutics股票老虎,Fate Therapeutics股票老虎国际,Fate Therapeutics行情,Fate Therapeutics股票行情,Fate Therapeutics股价,Fate Therapeutics股市,Fate Therapeutics股票价格,Fate Therapeutics股票交易,Fate Therapeutics股票购买,Fate Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}